This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Haemonetics' Plasma Unit Grows, Global Expansion on Track
by Zacks Equity Research
Haemonetics' (HAE) Plasma arm steadily witnesses solid growth in the fiscal third quarter on 16% revenue rise at constant currency.
Why Is Haemonetics (HAE) Down 1.4% Since Last Earnings Report?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics (HAE) Earnings Top, Revenues Lag Estimates in Q3
by Zacks Equity Research
Haemonetics' (HAE) year-over-year earnings growth in Q3 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.
Haemonetics (HAE) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 6.78% and -1.14%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perrigo Stock Up as Appeal Date for Irish Tax Bill Nears
by Zacks Equity Research
Perrigo's (PRGO) shares rebound as the time to file an appeal against the Irish tax bill of $1.9 billion nears its deadline of Dec 28.
Perrigo Plunges on $1.9B Tax Bill From Irish Government
by Zacks Equity Research
Perrigo (PRGO), in a SEC filing, reports a $1.9 billion tax bill from Irish revenue department related to its subsidiary, Elan Pharma.
Here's Why You Should Buy Haemonetics (HAE) Stock Right Now
by Zacks Equity Research
Haemonetics (HAE) continues to witness strong growth in Plasma franchise.
Haemonetics (HAE) Down 8.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should iShares Morningstar Small-Cap ETF (JKJ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKJ
Haemonetics Strong on Plasma & Hemostasis Management Units
by Zacks Equity Research
Haemonetics (HAE) sees encouraging growth at the North America Plasma revenues on strong disposables along with growing software revenues.
Haemonetics (HAE) Earnings & Revenues Beat Estimates in Q2
by Zacks Equity Research
Haemonetics' (HAE) year-over-year growth in Q2 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.
Will New Products Drive TransEnterix's (TRXC) Q3 Earnings?
by Zacks Equity Research
Among the recent developments, in the third quarter, TransEnterixs (TRXC) gains an FDA approval for its additional 5 millimeter Senhance System instruments.
Can Dental Growth Drive Henry Schein's (HSIC) Q3 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is well placed to gain from the digitalization trend in the global dental market.
What's Setting the Tone for Hologic's (HOLX) Q4 Earnings?
by Zacks Equity Research
Strength in the Breast Health business, Panther system and increasing utilization of Aptima women's health assays will boost Hologic's (HOLX) top line in Q4.
Will CVS Health's (CVS) PBM Strength Boost Q3 Earnings?
by Zacks Equity Research
Despite a challenging pricing scenario, CVS Health (CVS) is currently gaining on high level of service and execution as well as a competitive pricing along with unique integrated model.
Haemonetics (HAE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medical Product Stocks to Trump Estimates in Q3 Earnings
by Zacks Equity Research
Here we analyze the favorable factors that are likely to boost results of medical product companies in Q3.
Will Obalon's (OBLN) Q3 Earnings Reflect Growth in U.S.?
by Zacks Equity Research
Obalon (OBLN) is expected to register robust U.S. revenues in Q3, backed by higher reorders from existing accounts and new order bookings.
What's in Store for Integer Holdings (ITGR) in Q3 Earnings?
by Zacks Equity Research
The Cardio & Vascular product line to boost Integer Holdings' (ITGR) top line in Q3. The upside will be driven by strong revenues in the peripheral vascular, neurovascular and electrophysiology markets.
ResMed (RMD) Looks Good: Stock Adds 5.7% in Session
by Zacks Equity Research
ResMed (RMD) shares rose nearly 6% in the last trading session, amid huge volumes.
Should iShares Morningstar Small-Cap ETF (JKJ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKJ
Should iShares Morningstar Small-Cap ETF (JKJ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKJ
Why Is Haemonetics (HAE) Up 9.2% Since Last Earnings Report?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics Strong on Plasma Unit Amid Blood Center Weakness
by Zacks Equity Research
Haemonetics (HAE) witnesses strong growth in Plasma franchise. Dullness in Blood Center business prevails.